APAC Breast Biopsy Market

APAC Breast Biopsy Market Size (2024 to 2029)

As per the research report, the Asia Pacific Breast Biopsy Market size was predicted at USD 132.74 million in 2024. It is forecasted to grow at a CAGR of 11.3% and be worth USD 226.71 million by 2029.

Factors such as an increase in the number of breast cancer screening programs as a result of government efforts, as well as an increase in demand for minimally invasive and non-invasive procedures due to various benefits such as faster recovery and less pain, are primarily expected to fuel the breast biopsy market in the Asia-Pacific. Under the supervision of ultrasound, a 6mm Bergstrom side-cutting biopsy needle was a successful instrument for obtaining large parts of the tissue. Increased awareness of early detection of breast cancer and improved reimbursement circumstances are also driving market expansion.

Furthermore, the increase in population, healthcare expenditure, and public-sector measures to address female health issues benefit the market for breast biopsy devices. New instruments and procedures have substantially impacted the breast biopsy market's overall growth. In the medical industry, identifying cancer cells and DNA fragments has been a problem; nevertheless, liquid biopsy has aided medical practitioners in precisely identifying circulating tumor cells. The liquid biopsy can identify all of the genetic complexity of cancers seen in human breasts and prevent them from migrating to other parts of the body. The appeal of the liquid biopsy has created a lucrative opportunity for the overall APAC breast biopsy market's growth.

The risk of infection associated with using biopsy needles and the stringent regulatory approval procedures are projected to restrict expansion. Breast biopsy instruments are expected to face challenges in the forecast period due to this nation's underdeveloped healthcare infrastructure and lack of resources. Some over-the-counter medications, herbs, medicines, vitamins, and mineral supplements must be avoided after surgery because they may conflict with the medication given during the biopsy. The disease worsens if the patient does not follow the medical practitioner's advice. Such difficulties are essential stumbling blocks to the Breast biopsy market's expansion. The market's high cost also stifles the procedure's high cost, risk, and adverse side effects.

This research report on the Asia-Pacific breast biopsy market has been segmented and sub-segmented into the following categories.

APAC Breast Biopsy Market Analysis By Type

• Open Surgical Breast Biopsy
• Needle Breast Biopsy

APAC Breast Biopsy Market Analysis By Product

• Biopsy Tables
• Localization Wires
• Biopsy Needles
• Guidance Systems
• Others

APAC Breast Biopsy Market Analysis By Guidance

• MRI-Guided Breast Biopsy
• Mammography-Guided Stereotactic Breast Biopsy
• Ultrasound-Guided Breast Biopsy
• Other Techniques

APAC Breast Biopsy Market Analysis By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Asia-Pacific is expected to have a significant share of the worldwide breast biopsy market during the forecast period. This is because breast cancer screening programs are becoming more prevalent. The rapidly evolving healthcare infrastructure in growing nations such as China, India, and South Korea drives the Asia-Pacific breast biopsy market. This has resulted in significant investments in advanced systems by hospitals and breast clinics. Apart from that, factors such as the rising prevalence of breast cancer, the increasing awareness among people, and funding for breast cancer research are fuelling the market growth in the region. Growing acceptance of improved medical technologies and increased development by cancer diagnostics organizations are prominent factors driving the breast biopsy market. A significant driver boosting the breast biopsy market during the forecast period is the rising acceptance of modern medical technologies and increased development by companies involved in cancer diagnosis.

KEY MARKET PLAYERS

Companies playing a significant role in the APAC breast biopsy market profiled in the report are Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule medical Devices LLC., Ethicon Endo-Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL.